Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01056276 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT01056276 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 59 participants.
The verdict
NCT01056276, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and non-overlapping toxicities.
Interventions
- DRUG Dexamethasone
- DRUG Bendamustine
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2010-05 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01056276
The ClinicalTrials.gov registry entry for NCT01056276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01056276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01056276 about?
NCT01056276 is a clinical study titled "Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy". In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and non-overlapping toxicities.
What is the current status of trial NCT01056276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2010-05. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01056276?
The interventions under investigation include: Dexamethasone (DRUG), Bendamustine (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01056276?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.